We have previously reported that B-9-3 regulated the recruitment of immune cells in the tumor microenvironment and inhibited tumor angiogenesis by blocking the transforming growth factor receptor 1 (TGFβRI) and vascular endothelial growth factor receptor 2 (VEGFR2) signaling pathways, demonstrating significant anticancer effects in vitro and in vivo (Meixin and Youran, 2024; Zhang, 2020). The gene discussed is KDR; the disease is neoplasm.